Tag Archives: NASDAQ:ALRN

Aileron Therapeutics (ALRN) Receives a Rating Update from a Top Analyst

H.C. Wainwright analyst Edward White maintained a Buy rating on Aileron Therapeutics (ALRN – Research Report) today and set a price target of $2.00. The company’s shares closed last Monday at $1.14. According to TipRanks.com, White is a top 100

JonesTrading Keeps a Buy Rating on Aileron Therapeutics (ALRN)

JonesTrading analyst Soumit Roy reiterated a Buy rating on Aileron Therapeutics (ALRN – Research Report) today and set a price target of $5.00. The company’s shares closed last Thursday at $1.09. According to TipRanks.com, Roy is a 5-star analyst with

Analysts’ Top Healthcare Picks: Aileron Therapeutics (ALRN), BioMarin Pharmaceutical (BMRN)

There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Aileron Therapeutics (ALRN – Research Report) and BioMarin Pharmaceutical (BMRN – Research Report) with bullish sentiments. Aileron Therapeutics (ALRN) In a report

Aileron Therapeutics (ALRN) Received its Third Buy in a Row

After H.C. Wainwright and Canaccord Genuity gave Aileron Therapeutics (NASDAQ: ALRN) a Buy rating last month, the company received another Buy, this time from JonesTrading. Analyst Soumit Roy reiterated a Buy rating on Aileron Therapeutics today and set a price

Canaccord Genuity Sticks to Their Buy Rating for Aileron Therapeutics (ALRN)

In a report released yesterday, John Newman from Canaccord Genuity maintained a Buy rating on Aileron Therapeutics (ALRN – Research Report), with a price target of $5.00. The company’s shares closed last Tuesday at $0.63. According to TipRanks.com, Newman is

Analysts Offer Insights on Healthcare Companies: Aileron Therapeutics (NASDAQ: ALRN) and Zimmer Biomet Holdings (NYSE: ZBH)

There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Aileron Therapeutics (ALRN – Research Report) and Zimmer Biomet Holdings (ZBH – Research Report) with bullish sentiments. Aileron Therapeutics (ALRN) In a